Business Wire

Global Tech and Durables Market in Recovery Mode

3.9.2024 16:00:00 EEST | Business Wire | Press release

Share

2024 looks like a better year than 2023 for the global Consumer Tech and Durables (T&D) market. Inflation rates are easing, consumer confidence is rising, summer bookings are returning to pre-pandemic levels, and major sporting events such as the Paris Olympics and the European Football Championship in Germany are triggering demand.

At the mid-year point, most T&D segments are showing steady growth, and the market overall is slowly recovering, albeit still in negative territory. From January to June 2024, the global T&D market recorded a slight decrease in revenue of minus 0.6 percent to 395 billion US-dollars compared to the same period last year, and NIQ-GfK experts are forecasting that the trend will continue, with stable revenue of minus 0.1 percent for the full year 2024.

Omnichannel remains king

Inflation and high prices continue to be a top concern of consumers worldwide (GfK Consumer Life study), and 57 percent of global consumers are prepared to switch stores to manage costs (NIQ Consumer Outlook report 2024).

“Omnichannel retailing remains popular, with 36 percent of total global T&D sales made online in the first half of 2024 – an increase of 0.4 percent from last year. But consumer behavior is changing, driven by price concerns and a desire for best value for money. The global T&D market must keep pace to achieve long-term, sustainable growth,” explains Nevin Francis, GfK's insights expert for the Tech and Durables industry.

The progress of Chinese online retailers in Europe is quite notable. In the first half of 2024, the Chinese e-commerce retailer, Temu, ranked second in terms of order volume for computers and electronics, although its average order value is lower due to the smaller-ticket price of items. According to Foxintelligence by NielsenIQ, 77 percent of German Temu shoppers in the last 60 days were repeat buyers.

Looking at regional differences, consumer spending caution varies depending on purchasing power and local price levels. While Western Europe and Developed Asia experienced year-on-year revenue declines in the first half of the year (1 percent and 9 percent respectively), Eastern Europe (plus 4 percent) and the Middle East (plus 8 percent) grew, and Emerging Asia also returned to growth.

“Price-conscious consumers are increasingly looking for value for money. As a result, the 15 promotional weeks in a year, such as the mid-year promotion and Black Friday already account for 34 percent of annual T&D revenue,” summarizes Nevin Francis. “Retailers and manufacturers must balance the demand for premiumization with a good price-performance ratio, while focusing on their unique selling proposition. To find that sweet spot, they need to know their target group better than ever before.”

Specific trends driving the half-year results for global T&D

GfK panel data shows that the Telecom and Photo categories are back in the black in the first half of 2024, while other T&D categories regaining momentum and starting to recover:

  • Consumer Electronics (TVs, soundbars, etc.): minus 2 percent
  • Telecom (Smartphones, etc.): plus 2 percent
  • IT (Mobile PCs, hardware, etc.): minus 5 percent
  • Small Domestic Appliances (Fryers, mixers, etc.): minus 1 percent
  • Major Domestic Appliances (ACs, ovens, etc.): minus 2 percent 

Growth in the homeappliances sector is being driven by three key consumer desires: sustainability, simplification and AI-powered intelligence. As personalized features and AI assistants make everyday household tasks more efficient and easier, demand for related devices such as smart ovens and cookers (up 30 percent year-over-year in revenue January 2024 - June 2024) has noticeably increased. In general, convenience-oriented appliances such as robot vacuum cleaners and fully automatic espresso machines (up 9 percent and 7 percent respectively) and more environmentally friendly products such as A-labelled washing machines (up 39 percent in Europe) have gained ground.

In the IT sector, on the other hand, it is still all about premiumization, especially more memory in devices. In laptops, 16GB RAM is becoming the new standard, with sales volume up 3 percent in the first half of 2024 compared to the same period last year, replacing older models. The same is true for media tablets, where 8GB RAM devices with larger displays of 9 inches and above dominate with an impressive 58 percent volume growth rate. In addition, consumers are upgrading their IT accessories, such as Bluetooth keyboards (up 18 percent) and monitors with refresh rates above 240 Hz (up 90 percent).

In contrast to the B2C market, which is slowly recovering, the B2B market is still stuck in the red, according to GfK's distribution panel, with revenues down 6 percent year-on-year in the first half of 2024. Despite this downturn, there are positive signals in certain areas of the mass market. For example, processors (up 4 percent) are growing year-over-year in the first half of 2024. In addition, demand for software was up 8 percent, driven by an increased focus on security and collaboration solutions in the business sector. A standout success in the B2B market is AR/VR glasses, which – although still a niche category – achieved impressive growth of 80 percent, driven mainly by successful product launches beginning of the year.

About the method

Through its retail panels, GfK regularly collects POS (point of sales) data in more than 70 countries worldwide for the consumer electronics, photography, telecommunications, information technology, office equipment, and small and large household appliances sectors. All figures are according to GfK panel market, with global data excluding North America and presented in US dollars NSP (non-subsides price), except stated otherwise.

GfK – a NielsenIQ company

For 90 years, we have earned the trust of our clients around the world by solving critical questions in their decision-making process. We fuel their growth by providing a complete understanding of their consumers’ buying behavior, and the dynamics impacting their markets, brands and media trends. In 2023, GfK combined with NielsenIQ, bringing together two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights - delivered with advanced analytics through state-of-the-art platforms - GfK drives “Growth from Knowledge”.

For more information, visit GfK.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903945066/en/

Contacts

Eva Böhm
Public Relations
T +49 911 395 4440
Public.relations@smb.nielseniq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye